Randomized trial evaluates overall survival and progression-free survival in glioblastoma, suggesting no benefit from bevacizumab.
First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. Progression-free survival was prolonged but did not reach the prespecified improvement target. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00884741.).
No takes yet. Share an insight, caveat, or question.
Gilbert et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: